Reported Earnings • Apr 22
Full year 2025 earnings released: HK$0.025 loss per share (vs HK$0.026 profit in FY 2024) Full year 2025 results: HK$0.025 loss per share (down from HK$0.026 profit in FY 2024). Revenue: HK$1.64b (flat on FY 2024). Net loss: HK$26.8m (down 193% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Mar 24
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Dan Cao was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 14
Full year 2025 earnings released: HK$0.025 loss per share (vs HK$0.026 profit in FY 2024) Full year 2025 results: HK$0.025 loss per share (down from HK$0.026 profit in FY 2024). Revenue: HK$1.64b (flat on FY 2024). Net loss: HK$26.8m (down 193% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Mar 14
Tian An Medicare Limited, Annual General Meeting, May 18, 2026 Tian An Medicare Limited, Annual General Meeting, May 18, 2026. Announcement • Mar 03
Tian An Medicare Limited to Report Fiscal Year 2025 Results on Mar 13, 2026 Tian An Medicare Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 13, 2026 Board Change • Feb 20
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Dan Cao was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jan 16
Tian an Medicare Limited Announces Re-Designation of Zhou Haiying as Non-Executive Director from Executive Director, Effective 16 January 2026 The board of directors of Tian An Medicare Limited (Company) announced that Mr. Zhou Haiying (Mr. Zhou) has been re-designated from an Executive Director to a Non-Executive Director of the Company (the "Re-designation") with effect from 16 January 2026. Mr. Zhou, aged 55, was appointed as an Executive Director of the Company in December 2018. Mr. Zhou graduated from Jiangxi University of Finance and Economics with a Bachelor's Degree. He acts as the general manager of the finance management department of Tsinghua Tongfang Co. Ltd., since August 2024. From April 2020 to August 2024, Mr. Zhou acted as the chief operating officer of THTF, and from January 2018 to February 2020, he acted as a financial controller and the chief financial officer of THTF. From January 2020 to October 2023, Mr. Zhou was a non- executive director of Neo-Neon Holdings Limited. From June 2003 to January 2018, he has served successively as a senior manager, the deputy director of the finance department, head of asset management department, the general manager of the capital finance department and an assistant to the president of Tsinghua Holdings Co. Ltd. In addition, he also worked as a director of Liaoning Road & Bridge Construction Corporation, a director of Beijing Huahuan Electronics Co. Ltd. and the supervisor of Unisplendour Corporation Limited. Board Change • Dec 05
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Dan Cao was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 11
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Dan Cao was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 16
First half 2025 earnings released: EPS: HK$0.011 (vs HK$0.02 in 1H 2024) First half 2025 results: EPS: HK$0.011 (down from HK$0.02 in 1H 2024). Revenue: HK$783.1m (down 4.7% from 1H 2024). Net income: HK$12.0m (down 45% from 1H 2024). Profit margin: 1.5% (down from 2.6% in 1H 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 04
First half 2025 earnings released: EPS: HK$0.011 (vs HK$0.02 in 1H 2024) First half 2025 results: EPS: HK$0.011 (down from HK$0.02 in 1H 2024). Revenue: HK$783.1m (down 4.7% from 1H 2024). Net income: HK$12.0m (down 45% from 1H 2024). Profit margin: 1.5% (down from 2.6% in 1H 2024). Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. New Risk • Aug 02
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.2% Last year net profit margin: 1.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin). Announcement • Jul 22
Tian An Medicare Limited to Report Second Half, 2025 Results on Aug 01, 2025 Tian An Medicare Limited announced that they will report second half, 2025 results on Aug 01, 2025 New Risk • Jul 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improves as stock rises 43% After last week's 43% share price gain to HK$1.14, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 13x in the Healthcare industry in Hong Kong. Total loss to shareholders of 20% over the past three years. New Risk • May 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$758.2m (US$97.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (HK$758.2m market cap, or US$97.0m). Upcoming Dividend • May 16
Upcoming dividend of HK$0.02 per share Eligible shareholders must have bought the stock before 23 May 2025. Payment date: 27 June 2025. Payout ratio is on the higher end at 75% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (4.1%). Declared Dividend • Apr 30
Dividend increased to HK$0.02 Dividend of HK$0.02 is 100% higher than last year. Ex-date: 23rd May 2025 Payment date: 27th June 2025 Dividend yield will be 2.6%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is covered by earnings (75% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 68% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Board Change • Apr 30
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Dan Cao was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Apr 13
Full year 2024 earnings released: EPS: HK$0.026 (vs HK$0.016 in FY 2023) Full year 2024 results: EPS: HK$0.026 (up from HK$0.016 in FY 2023). Revenue: HK$1.63b (up 3.7% from FY 2023). Net income: HK$28.8m (up 96% from FY 2023). Profit margin: 1.8% (up from 0.9% in FY 2023). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Declared Dividend • Mar 13
Dividend increased to HK$0.02 Dividend of HK$0.02 is 100% higher than last year. Ex-date: 23rd May 2025 Payment date: 27th June 2025 Dividend yield will be 2.6%, which is lower than the industry average of 3.7%. Reported Earnings • Mar 12
Full year 2024 earnings released: EPS: HK$0.027 (vs HK$0.012 in FY 2023) Full year 2024 results: EPS: HK$0.027 (up from HK$0.012 in FY 2023). Revenue: HK$1.63b (up 3.7% from FY 2023). Net income: HK$28.8m (up 155% from FY 2023). Profit margin: 1.8% (up from 0.7% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Feb 18
Tian An Medicare Limited to Report Q2, 2025 Results on Feb 28, 2025 Tian An Medicare Limited announced that they will report Q2, 2025 results on Feb 28, 2025 Board Change • Feb 10
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Non-Executive Director Dan Cao was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. New Risk • Jan 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jan 10
Tian an Medicare Limited Announces Change of Company Secretary The board of directors of Tian An Medicare Limited announced that Mr. Kong Muk Yin has resigned as the company secretary of the company with effect from 10 January 2025. The board announced that Ms. Sit Po Ling has been appointed as the Company Secretary and the authorised representative of the Company to replace the existing Authorised Representative, namely Mr. Mark Wong Tai Chun both with effect from 10 January 2025. Ms. Sit is an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. She holds a Bachelor's Degree in Business Administration and a Master's Degree in Corporate Governance. Ms. Sit is also the company secretary of Asiasec Properties Limited, the fellow subsidiary of the Company, the shares of which are listed on the Main Board of the Stock Exchange. Mr. Kong will remain as Executive Director of the Company after his resignation as Company Secretary while Mr. Wong will remain as Non-Executive Director of the Company after he ceased to be an Authorised Representative. Announcement • Dec 30
Tian An Medicare Limited Announces Board Changes Tian An Medicare Limited announced that Mr. Zhang Jian ("Mr. Zhang") has tendered his resignation as an independent non- executive director of the Company (the "Independent Non-Executive Director") and a member of each of the audit committee, nomination committee and remuneration committee of the Company with effect from 30 December 2024 in order to devote more time to his other commitments. Mr. Zhang confirmed that he has no disagreement with the Board and there is no other matter with respect to his resignation that need to be brought to the attention of the shareholders of the Company (the "Shareholders") and The Stock Exchange of Hong Kong Limited. Mr. Cao Dan ("Mr. Cao") has been appointed as an Independent Non-Executive Director and a member of each of the audit committee, nomination committee and remuneration committee of the Company with effect from 30 December 2024. Mr. Cao, aged 49, holds a bachelor degree in law from East China University of Political Science and Law and a master degree in law from Fudan University. Mr. Cao is currently the managing partner of Han Yuan & Partners and an arbitrator of the China Maritime Arbitration Commission. Mr. Cao was a judge of the Shanghai Maritime Court of the People's Republic of China (the "PRC"). He has extensive professional experience in both non-litigation and litigation areas. The former includes venture capital and corporate mergers and acquisitions, and the latter covers maritime and intellectual property. Ms. Zhang Yuanyuan ("Ms. Zhang") has been appointed as a non-executive director of the Company with effect from 30 December 2024. Ms. Zhang, aged 47, is currently the vice president, the secretary to the board of directors and the chief capital operating officer of Tsinghua Tongfang Co. Ltd. and is also currently the executive director, the chairman of the board of directors, the president and the chief executive officer of Neo-Neon Holdings Limited. She is experienced in the areas of capital operation, legal affairs, finance management and investment management, and has been successively served as several senior management positions in THTF and its subsidiaries since May 2016. Ms. Zhang graduated in 1999 with a bachelor degree and in 2002 with a master degree both majoring in law from Dongbei University of Finance and Economics. She obtained lawyers' qualification in the PRC in 2001. Mr. Zhang ceased to be a member of each of the audit committee, nomination committee and remuneration committee of the Company; and Mr. Cao has been appointed as a member of each of the audit committee, nomination committee and remuneration committee of the Company. New Risk • Oct 03
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$760.2m (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Sep 22
First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 in 1H 2023) First half 2024 results: EPS: HK$0.02 (up from HK$0.002 in 1H 2023). Revenue: HK$821.5m (up 8.0% from 1H 2023). Net income: HK$21.7m (up HK$20.3m from 1H 2023). Profit margin: 2.6% (up from 0.2% in 1H 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 05
First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 loss in 1H 2023) First half 2024 results: EPS: HK$0.02 (up from HK$0.002 loss in 1H 2023). Revenue: HK$821.5m (up 8.0% from 1H 2023). Net income: HK$21.7m (up HK$23.4m from 1H 2023). Profit margin: 2.6% (up from net loss in 1H 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Announcement • Jul 23
Tian An Medicare Limited to Report Q4, 2024 Results on Aug 02, 2024 Tian An Medicare Limited announced that they will report Q4, 2024 results on Aug 02, 2024 Upcoming Dividend • May 23
Upcoming dividend of HK$0.01 per share Eligible shareholders must have bought the stock before 30 May 2024. Payment date: 02 August 2024. Trailing yield: 1.5%. Lower than top quartile of Hong Kong dividend payers (7.4%). Lower than average of industry peers (3.4%). Reported Earnings • Apr 18
Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022) Full year 2023 results: EPS: HK$0.012 (up from HK$0.17 loss in FY 2022). Revenue: HK$1.57b (up 9.1% from FY 2022). Net income: HK$11.3m (up HK$134.9m from FY 2022). Profit margin: 0.7% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Announcement • Mar 21
China Medical & Healthcare Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 02 August 2024 China Medical & HealthCare Group Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023, payable on 02 August 2024. Record date is 04 June 2024. Ex-dividend date is 30 May 2024. Date of shareholders' approval is 20 May 2024. Reported Earnings • Mar 19
Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022) Full year 2023 results: EPS: HK$0.012 (up from HK$0.17 loss in FY 2022). Revenue: HK$1.57b (up 9.1% from FY 2022). Net income: HK$11.3m (up HK$134.9m from FY 2022). Profit margin: 0.7% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Announcement • Mar 18
China Medical & HealthCare Group Limited, Annual General Meeting, May 20, 2024 China Medical & HealthCare Group Limited, Annual General Meeting, May 20, 2024, at 11:00 China Standard Time. Location: Plaza 1-2, Basement 3, Novotel Century Hong Kong 238 Jaffe Road Wan Chai Hong Kong Agenda: To consider and approve the Share Premium Reduction. Announcement • Mar 06
China Medical & HealthCare Group Limited to Report Fiscal Year 2023 Final Results on Mar 15, 2024 China Medical & HealthCare Group Limited announced that they will report fiscal year 2023 final results on Mar 15, 2024 New Risk • Feb 06
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: HK$760.2m (US$97.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (HK$760.2m market cap, or US$97.2m). Announcement • Jan 10
China Medical & Healthcare Group Limited Provides Earnings Guidance for Eleven Months Ended 30 November 2023 China Medical & HealthCare Group Limited provided earnings guidance for eleven months ended 30 November 2023. The Group is expected to record a profit attributable to Shareholders in the estimated range of approximately HKD 11 million to HKD 31 million for the eleven months ended 30 November 2023 as compared with (a) the loss for the corresponding period in 2022; and (b) the loss of approximately HKD 123.6 million for the year ended 31 December 2022. This was mainly due to (i) the increase in revenue from operations of the healthcare division amid the relaxation of epidemic preventive measures and the resumption of economic and social activities in the Peoples' Republic of China; (ii) the decrease in cost of medical consumables; and (iii) the increase in interest income from bank deposits but were partially off-set by (iv) the increase in cost of pharmaceutical and medicine; and (v) the increase in employee benefits expense. Announcement • Nov 22
China Medical & Healthcare Group Limited Announces Company Secretary and Authorised Representative Changes The board of directors of China Medical & HealthCare Group Limited announces that Ms. Leung Yuk Yi ("Ms. Leung") has resigned as the company secretary of the Company, an authorised representative of the Company Kong) with effect from 21 November 2023. Ms. Leung has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange or the shareholders of the Company. The Board announced that Mr. Kong Muk Yin ("Mr. Kong"), an Executive Director of the Company, has been appointed as the Company Secretary with effect from 21 November 2023. Mr. Kong graduated from the City University of Hong Kong with a Bachelor's Degree in Business Studies. He is a fellow member of The Association of Chartered Certified Accountants, a member of the Hong Kong Institute of Certified Public Accountants and a Chartered Financial Analyst and he has extensive experience in corporate finance, financial management, accounting and auditing. The Board further announces that following the resignation of Ms. Leung, Mr. Mark WongTai Chun ("Mr. Wong"), a Non-Executive Director of the Company, has been appointed as an authorised representative of the Company under Rule 3.05 of the Listing Rules with effect from 21 November 2023. Announcement • Oct 11
China Medical & HealthCare Group Limited Announces Change in the Composition of the Board of Directors and Change of Members of the Board Committees The board of directors of China Medical & HealthCare Group Limited announced that with effect from 10 October 2023, the composition of the board of directors of the Company and the members of the board committees of the Company have been changed. Mr. Lee Seng Hui is appointed as a Non-Executive Director and the Chairman of the Company. Mr. Lee, aged 54, chief executive of Allied Group Limited, since January 1998, was appointed as a non-executive director of AGL in July 1992 and became an executive director of AGL in December 1993. Mr. Lee is also a director of certain subsidiaries of AGL. He graduated from the Law School of the University of Sydney with Honours. Previously, he worked with Baker & McKenzie and N M Rothschild & Sons (Hong Kong) Limited. Mr. Lee is the chairman and a non- executive director of Tian An China Investments Company Limited and a non-executive director of APAC Resources Limited. He is the non-executive chairman of Mount Gibson Iron Limited. Mr. Lee was the chief executive and an executive director of Allied Properties (H.K.) Limited between June 2010 and December 2020. Mr. Mark Wong Tai Chun is appointed as a Non-Executive Director of the Company. Mr. Wong, aged 59, took up the post of director of investment of AGL, the ultimate holding company of the Company, in September 2007. Mr. Wong is also a director of certain subsidiaries of AGL. He has a Master's Degree in Business Administration and is a fellow of the Hong Kong Institute of Certified Public Accountants, the Association of Chartered Certified Accountants, The Chartered Governance Institute and The Hong Kong Chartered Governance Institute. He is also an alternate director to Mr. Arthur George Dew in APAC, Tanami Gold NL, Dragon Mining Limited and Tian An Australia Limited. Tanami Gold and Tian An Australia are companies listed on the Australian Securities Exchange. He was also a director of each of APL and SHK Hong Kong Industries Limited. Mr. Lai Hin Wing Henry Stephen announced the resignation as a Non-Executive Director of the Company. Mr. Lai tendered his resignation as a Non-Executive Director of the Company on 9 October 2023 in order to devote more time to his other business. The Board resolved to accept the resignation of Mr. Lai with effect from 10 October 2023. Mr. Wong has been appointed as a member of each of the Remuneration Committee and environmental, social and governance committee and the chairman of investment committee of the Company; and Mr. Kong Muk Yin has been appointed as the chairman of each of the nomination committee and executive committee of the Company. Announcement • Oct 07
Tian An China Investments Company Limited (SEHK:28) completed the acquisition of 18.13% stake in China Medical & HealthCare Group Limited (SEHK:383) from its shareholders for approximately HKD 180 million. Tian An China Investments Company Limited (SEHK:28) made an offer to acquire the remaining stake in China Medical & HealthCare Group Limited (SEHK:383) from its shareholders at HKD 0.89 per share on June 16, 2023. TACI will fund the offer from the unsecured facility provided by Lee and Cashplus. The CMH Independent Board Committee, comprising Gao Zhaoyuan, Zhang Jian and Xia Xiaoning, has been established to advise the CMH Independent Shareholders in relation to the terms and conditions of the CMH Offer. The offer is conditional to a minimum tender of 50% stake. As of August 31, 2023 The CMH Independent Board Committee recommends the shareholder to accept the offer. The condition of the CMH Offer had been fulfilled and the CMH Offer became unconditional in all respects on September 21, 2023. Transaction is expected to close on September 21, 2023. The offer will remain open for acceptance until on October 5, 2023. Emperor Securities Limited acted as financial advisor to China Medical & HealthCare Group Limited and Yu Ming Investment Management Limited acted as a financial advisor to Tian An China Investments Company Limited.
Tian An China Investments Company Limited (SEHK:28) completed the acquisition of 18.13% stake in China Medical & HealthCare Group Limited (SEHK:383) from its shareholders for approximately HKD 180 million on October 5, 2023. As part of the offer, valid acceptance of 196,860,010 CMH Offer Shares. Announcement • Oct 06
China Medical & Healthcare Group Limited Announces Resignation of Chong Sok Un as Executive Director and Deputy Chairman and Change in Composition of the Board Committees The board of directors (the ‘Board’) of China Medical & HealthCare Group Limited (the ‘Company’) announced that Ms. Chong Sok Un (‘Ms. Chong’) has stepped down and resigned as an executive director and the deputy chairman of the company and she has also ceased to be the chairman of each of the nomination committee, executive committee and investment committee and a member of the remuneration committee of the company with effect from 5 October 2023 in order to devote more time to her other commitments. Ms. Chong has been a director of the Company since 2002. She was appointed as a director and chairman of the Company on 23 August 2002 and was subsequently re-designated as deputy chairman of the Company on 16 December 2015. The board announced that with effect from 5 October 2023, the composition of the Board Committees of the Company has been changed as follows: Ms. Chong ceased to be the chairman of each of the nomination committee, executive committee and investment committee and a member of the remuneration committee of the company. Reported Earnings • Aug 20
First half 2023 earnings released: HK$0.002 loss per share (vs HK$0.061 loss in 1H 2022) First half 2023 results: HK$0.002 loss per share (improved from HK$0.061 loss in 1H 2022). Revenue: HK$761.0m (up 3.4% from 1H 2022). Net loss: HK$1.76m (loss narrowed 96% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. New Risk • Aug 20
New major risk - Revenue and earnings growth Earnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (50% increase in shares outstanding). Announcement • Aug 04
China Medical & HealthCare Group Limited to Report Second Half, 2023 Results on Aug 18, 2023 China Medical & HealthCare Group Limited announced that they will report second half, 2023 results on Aug 18, 2023 Announcement • Jul 12
China Medical & HealthCare Group Limited Provides Group Earnings Guidance for the Five Months Ended 31 May 2023 China Medical & HealthCare Group Limited provided group earnings guidance for the five months ended 31 May 2023. For the five months, the Group is expected to record a loss attributable to the Shareholders for the five months ended 31 May 2023 which represents an approximately 87% to 97% decrease in loss as compared with (i) the loss for the corresponding period in 2022; and (ii) the loss for the six months ended 30 June 2022 respectively. This was mainly due to (i) the increase in revenue from operations of the healthcare division; and (ii) the decrease in cost of medical consumables but was partially off-set by (iii) the increase in cost of pharmaceutical and medicine, amid the relaxation of epidemic preventive measures and the resumption of economic and social activities in the People's Republic of China. Reported Earnings • Mar 30
Full year 2022 earnings released: HK$0.17 loss per share (vs HK$0.19 loss in FY 2021) Full year 2022 results: HK$0.17 loss per share (improved from HK$0.19 loss in FY 2021). Revenue: HK$1.44b (down 1.8% from FY 2021). Net loss: HK$123.6m (loss narrowed 10.0% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 32% per year whereas the company’s share price has fallen by 28% per year. Announcement • Jan 21
China Medical & Healthcare Group Limited Provides Consolidated Earnings Guidance for the Eleven Months Ended 30 November 2022 China Medical & HealthCare Group Limited provided consolidated earnings guidance for the eleven months ended 30 November 2022. For the period, the company group is expected to record a loss attributable to shareholders of the Company ("Net Loss") for the eleven months ended 30 November 2022 which represents (a) an approximately 26% decrease as compared with the Net Loss for the corresponding period in 2021; (b) an approximately 30% to 50% decrease when compared with the Net Loss for the year ended 31 December 2021; but (c) an approximately 20% to 40% increase when compared with the Net Loss for the year ended 31 December 2021 excluding the one-off non-recurring item of impairment loss under expected credit loss model recognized on loan receivable. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Lisa Yang was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 27
First half 2022 earnings released: HK$0.003 loss per share (vs HK$0.005 loss in 1H 2021) First half 2022 results: HK$0.003 loss per share (up from HK$0.005 loss in 1H 2021). Revenue: HK$736.0m (up 3.9% from 1H 2021). Net loss: HK$43.9m (loss narrowed 41% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Non-Executive Director Lisa Yang was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 31
Full year 2021 earnings released: HK$0.009 loss per share (vs HK$0.008 loss in FY 2020) Full year 2021 results: HK$0.009 loss per share (down from HK$0.008 loss in FY 2020). Revenue: HK$1.46b (up 23% from FY 2020). Net loss: HK$137.3m (loss widened 23% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance. Reported Earnings • Oct 01
First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: HK$708.7m (up 50% from 1H 2020). Net loss: HK$73.9m (loss widened 5.5% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 30
First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: HK$708.7m (up 50% from 1H 2020). Net loss: HK$73.9m (loss widened 5.5% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 22% per year. Executive Departure • May 24
Executive Director has left the company On the 13th of May, Muk Yin Kong's tenure in the role of Executive Director ended. We don't have any record of a personal shareholding under Muk Yin's name. A total of 4 executives have left over the last 12 months. Executive Departure • May 24
Non-Executive Director has left the company On the 13th of May, Peng Wong's tenure as Non-Executive Director ended after 19.2 years in the role. We don't have any record of a personal shareholding under Peng's name. A total of 4 executives have left over the last 12 months. Executive Departure • Apr 18
Chairman Liye Zhou has left the company On the 15th of April, Liye Zhou's tenure as Chairman ended after 2.4 years in the role. We don't have any record of a personal shareholding under Liye's name. Liye is the only executive to leave the company over the last 12 months. Reported Earnings • Oct 02
First half earnings released Over the last 12 months the company has reported total losses of HK$80.7m, with earnings decreasing by HK$115.4m from the prior year. Total revenue was HK$1.10b over the last 12 months, down 8.1% from the prior year. 
